The c-myc proto-oncogene product, Myc, is a transcription factor that binds thousands of genomic loci 1 . Recent work suggested that rather than up-and downregulating selected groups of genes [1] [2] [3] , Myc targets all active promoters and enhancers in the genome (a phenomenon termed 'invasion') and acts as a general amplifier of transcription 4, 5 . However, the available data did not readily discriminate between direct and indirect effects of Myc on RNA biogenesis. We addressed this issue with genome-wide chromatin immunoprecipitation and RNA expression profiles during B-cell lymphomagenesis in mice, in cultured B cells and fibroblasts. Consistent with long-standing observations 6 , we detected general increases in total RNA or messenger RNA copies per cell (hereby termed 'amplification') 4, 5 when comparing actively proliferating cells with control quiescent cells: this was true whether cells were stimulated by mitogens (requiring endogenous Myc for a proliferative response) 7, 8 or by deregulated, oncogenic Myc activity. RNA amplification and promoter/enhancer invasion by Myc were separable phenomena that could occur without one another. Moreover, whether or not associated with RNA amplification, Myc drove the differential expression of distinct subsets of target genes. Hence, although having the potential to interact with all active or poised regulatory elements in the genome 4,5,9-11 , Myc does not directly act as a global transcriptional amplifier 4, 5 . Instead, our results indicate that Myc activates and represses transcription of discrete gene sets, leading to changes in cellular state that can in turn feed back on global RNA production and turnover.
We first analysed the genomic distribution of Myc during B-cell lymphomagenesis in vivo. We generated ChIP-seq profiles in B cells from young non-transgenic (control, C) and Em-myc transgenic littermates (pre-tumour, P), and in lymphomas arising in adult Em-myc animals (tumour, T) (Extended Data Fig. 1a-j) . Consistent with progressive increases in Myc mRNA and proteins levels, both binding intensity and the total number of binding sites progressively increased (around 7,000 sites in control, 17,000 in pre-tumour and 30,000 in tumour). Two-thirds of the Myc peaks in control were proximal to an annotated transcription start site (22 to 11 kb from the transcription start site, henceforth referred to as 'promoter'). Although the numbers of proximal and distal peaks both increased in pre-tumour and tumour, most of the new binding sites were distal, with equal proportions of intra-and extragenic locations, and increasing distances from the nearest transcription start site. To chart active promoters and enhancers 12, 13 , we profiled RNA polymerase II (RNAPII) and the histone marks H3K4me3, H3K4me1 and H3K27ac: as expected, these features marked virtually all Myc-bound promoters ( Fig. 1a and Extended Data Fig. 2a ) 9, 10 . Taking transcription start site annotations and H3K4me3 as references, Myc bound around 34% of active promoters in control, 66% in pre-tumour, and 87-94% in tumour samples. Instead, most unbound promoters showed no active histone marks or RNAPII (Fig. 1c) . Distal Myc-binding sites bore H3K4me1, the activation mark H3K27ac and to a lesser extent RNAPII, and showed the high H3K4me1/H3K4me3 ratios characteristic of enhancers (Fig. 1b, Extended Data Figs 2b, c and 3a) . Out of 20 H3K4me1-positive regions characterized as active enhancers in mouse B cells 14 , 2 were bound by Myc in control, 9 in pre-tumour and 18 in tumour (Extended Data Fig. 3b ). Instead, distal enhancers with no Myc showed H3K4me1 but little or no H3K27ac or RNAPII (Fig. 1d) , indicative of an inactive state. At both proximal and distal sites, the RNAPII and chromatin patterns in naive B cells (control sample) were similar to those in pre-tumour and tumour, preceding Myc at the same sites (Fig. 1a, b) , and their intensities correlated with those of Myc binding (Extended Data Fig. 2d ). In summary, Myc associated with regulatory elements that pre-existed in a poised or active state in naive B cells, the characteristic chromatin profiles of these sites anticipating Myc binding 9 . Most of these active elements were ultimately targeted in tumours, consistent with the concept of invasion 4 . We used RNA-seq to profile mRNA levels during tumour progression ( Fig. 2a and Extended Data Fig. 4a ). Normalizing to mean expression values yielded approximately 4,300 differentially expressed genes (DEGs) in pre-tumour and 3,900-4,600 in each tumour relative to control (Fig. 2b , c, Extended Data Fig. 4b and Supplementary Table 1) . Most of the DEGs in pre-tumour were also DEGs in a least one tumour, with an equivalent amount of tumour-specific DEGs. Of all DEGs in lymphomas, 1,914 (27.8%) were common to the three samples (Fig. 2b) . In all instances, more than half of DEGs showed increased expression, and approximately two-thirds of either class (up-or downregulated) had Myc bound to the promoter (Fig. 2c) . Interpreting changes in mRNA levels is confounded by the fact that Myc can enhance total cellular RNA content 4, 15 , an effect that was confirmed in our pre-tumour and tumour samples (note the parallel increases in cell size 16 , Fig. 2d , e). To account for this feature, we selected 754 mRNAs from our RNA-seq data and quantified them digitally with NanoString technology. This readily validated RNA-seq results, either as absolute or as differential expression relative to control (Extended Data Fig. 5a, b) . Normalizing the NanoString counts per cell equivalents revealed upward shifts in the pre-tumour and tumour samples (Extended Data Fig. 5 c, d) . As a consequence, very few downregulated mRNAs were left, most mRNAs showing modest to strong upregulation of mRNA copies per cell (Fig. 2f) . Importantly, this was observable whether or not Myc was bound to the promoter. Two implications follow from these data: first, rather than directly activating every promoter 4, 5 , Myc indirectly induced RNA amplification; second, direct regulatory cues (here the up-and downregulation of selected Myc-target genes) need to be discerned from global changes in RNA levels: this is achieved by normalizing RNA-seq profiles to mean expression, and not to cell equivalents However, tet-repressed P493-6 cells (0 h) were quiescent, and Myc activation induced cell growth and proliferation 17 (Extended Data Fig. 6d , e). P493-6 cells can also proliferate, albeit more slowly, upon activation of a viral EBNA2-ER fusion protein, eliciting expression of endogenous Myc ('Low') at lower levels than with tet-Myc ('High') 18 and intermediate levels of RNA amplification (Extended Data Fig. 6a , f-h). Thus, RNA amplification correlated not only with Myc levels, but also with cellular activation and growth rates, precluding clear conclusions on cause-to-effect relationships. The same limit may apply to tumour cell lines proliferating with different Myc levels 4 . RNA amplification was also reported upon stimulation of B cells with lipopolysaccharide (LPS), and was attributed to a direct effect of endogenous Myc
5
. We repeated these experiments in B cells homozygous for a conditional knockout allele (c-myc f/f ), allowing deletion of the gene before LPS treatment. Within the first 12 h, we confirmed a moderate increase in total RNA that was slightly reduced in the absence of Myc, as reported 5 (Extended Data Fig. 6i ). This was accompanied by a similar increase in cell size, followed by a Myc-dependent proliferative response 7 (Extended Data Fig. 6j, k) . However, both RNA content and cell size underwent striking increases at 24 h and 48 h, concomitant with plasma cell differentiation 6, 19 , which occurred even in the absence of Myc (Extended Data Fig. 6l) 
20
. Thus, once again, neither of the above experiments allow us to discriminate between direct and indirect RNA amplification by Myc, the latter following from the up-and downregulation of specific gene sets in those cells (for example, ref. 21).
To further address this issue, we used mouse 3T9 fibroblasts expressing a conditional Myc-oestrogen receptor chimaera (3T9 MycER ). Endogenous Myc levels in exponentially growing 3T9
MycER cells were sufficient to bind most of the active promoters (76%), as well as a sizeable number of active enhancers (33%). These were invaded further upon MycER activation (95% and 59%, respectively), whereas inactive elements remained unbound (Extended Data Fig. 7a-c) . Unlike the observations in B cells, MycER activation for up to 72 h caused no increase in cellular RNA content or cell size in fibroblasts (Fig. 3a, b) . RNA-seq at 4, 8 and 16 h post-activation revealed differential regulation of 1,400 to 2,300 genes, of which up to 46% were downregulated ( Fig. 3c and Supplementary Table  2) . A time-course with quantitative reverse transcription PCR (qRT-PCR) on several genes showed that expression changes were rapid and at plateau before 8 h (Extended Data Fig. 7d ). NanoString analysis validated the suppression and induction of selected mRNAs on a per-cell basis, without the general upregulation seen in B cells (Fig. 3d) . Most importantly, these changes in gene expression were transcriptional in nature, as selective sequencing of newly synthesized RNA isolated through 4-thiouridine incorporation (4sU-seq) yielded a pattern highly consistent with RNA-seq (Fig. 3c) . Hence, in either cell type, Myc contributed to direct transcriptional activation and repression of distinct groups of genes 1,2 . We then deleted the endogenous c-myc f/f gene in quiescent 3T9 fibroblasts, followed by serum stimulation. These cells showed a series of Myc-dependent effects, starting with the selective activation of approximately 300 Myc-dependent serum response (MDSR) genes in early G1, followed by S-phase entry 8 and by concomitant increases in either total RNA (back to the level observed in asynchronously growing cells: compare Fig. 3e and 3a) or mRNA molecules per cell as assayed by NanoString (Fig. 3f) . Serum also induced a moderate increase in size that was attenuated in the absence of Myc (Fig. 3g) . ChIP-seq analysis showed that endogenous Myc progressively binds a small subset of the sites bound by active MycER (Fig. 3h) . Hence, the RNA 'amplification' LETTER RESEARCH effect seen in stimulated B cells 5 also occurs in fibroblasts, but without complete invasion of active regulatory elements.
Several aspects of our data address the nature of chromatin invasion by overexpressed Myc. First, the binding hierarchies among different promoters were conserved at different Myc levels in either B cells or fibroblasts (Extended Data Fig. 8a) . Second, although all targeted promoters-even the weakest-were enriched for CpG islands and the H3K4me3 mark [8] [9] [10] 22 , only the strongest targets were enriched for consensus DNA binding motifs 8, 9 (Extended Data Fig. 8b ). The same was true at active enhancers, considering the H3K27ac mark. Third, MycERbound sites in fibroblasts were hypersensitive to DNase I digestion, indicating higher accessibility (Extended Data Fig. 7c) 
23
. Hence, invasion reflects increased interaction of overexpressed Myc with accessible chromatin domains, possibly favoured by recruitment (or tethering) by low-affinity protein-protein interactions 4, 8, 9, 11 , followed by non-specific engagement on DNA, and only at the strongest sites by sequencespecific DNA binding. The same order of events probably determines genome recognition by Myc or other transcription factors at physiological levels 11, 23 . These observations imply that: (1) Myc cannot act as a pioneer factor 23 but instead requires prior opening of the targeted elements, as also observed in reprogramming experiments 10 and (2) invasion shall not a priori be equated with a productive engagement of Myc on all crosslinked elements 11 . Altogether, our results show that promoter/enhancer invasion and RNA amplification are separable and functionally unrelated consequences of Myc overexpression. Thus, rather than the direct upregulation of every active gene (Fig. 4a) 4,5
, RNA amplification, when it occurs, is an indirect effect of Myc, which acts primarily through the differential regulation of specific groups of genes (Fig. 4b) . Among the functional categories enriched by Myc-regulated genes, we find a variety of DNA-and RNAassociated processes (Extended Data Fig. 9 ) that may be instrumental for RNA amplification either co-or post-transcriptionally, as exemplified by the Myc-repressed RNA-stabilizing factor ZFP36 (also known as TTP) 24 . Other cellular processes controlled by Myc and its target genes, such as nucleotide and energy metabolism, mitochondrial biomass, ribosome biogenesis or cell growth/size 3,16,17,25-27 may feed back on general transcriptional activity 28,29 (Fig. 4b ). These feedback mechanisms are highly conserved, pre-date Myc in evolution and rely in part on the global regulation of transcriptional elongation (or stalling), a phenomenon that was also directly attributed to Myc 4, 30 . Analysis of RNAPII distribution along Myc-induced genes in lymphomas and fibroblasts revealed composite increases in promoters and gene bodies, albeit without consistent effects on stalling indexes (Extended Data Fig. 10 ), warranting further discrimination between direct and indirect effects of this pervasive transcription factor. An essential corollary of our work is that the biology of Myc in physiology and disease must still be understood through comprehensive mapping of its target genes, as achieved here during B-cell lymphomagenesis. Our data constitute a unique resource for the functional characterization of these genes in tumour progression and maintenance. 
RESEARCH LETTER
cells, induction of the translation factor eIF4E led to augmented production of the nucleotide biosynthetic enzyme PRPS2, which in turn was required for the observed increase in RNA synthesis.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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METHODS
Primary mouse B cells and cell lines. C57BL/6 Em-myc transgenic mice 31 were monitored twice a week for lymphoma development by peripheral lymph node palpation 32 . In all experiments, we used gender-and age-matched mice (both males and females) without randomization or blinding. Tumours and lymphoid organs were dissected and processed for molecular analysis as described 33 . Briefly, for control (C) and pre-tumour (P) samples, spleens of 6-8-week-old mice with no infiltration of peripheral lymph nodes were used. We obtained single-cell suspensions by pressing the spleen through nylon cell strainers and subsequent hypotonic lysis of red blood cells. To isolate B cells, we incubated single-cell suspensions with B220 MicroBeads (Miltenyi Biotech) and enriched them by magnetic cell sorting (MACS), according to the manufacturer's instructions (Miltenyi Biotech). Lymphoma samples (or tumours, T) composed primarily of tumour cells, were dissected from infiltrated lymph nodes and not purified further. At this stage, all samples were fixed directly for chromatin immunoprecipitation (see below) without any in vitro treatment or culture. Experiments involving animals were performed in accordance with the Italian laws (D.L.vo 116/92 and following additions), which enforce EU 86/609 directive (Council Directive 86/609/EEC of 24 November 1986 on the approximation of laws, regulations and administrative provisions of the Member States regarding the protection of animals used for experimental and other scientific purposes).
P493-6 cells 34 were cultured in RPMI medium with 10% tetracycline-free serum, 2 mM L-Gln 1% penicillin/streptomycin and non-essential amino acids (NEAA) with either: (1) 0.2 mg ml 21 tetracycline (Sigma, T7660), (2) no additive or (3) 200 nM OHT and 0.2 mg ml 21 tetracycline, corresponding to the repressed (or 0 h), induced (or High Myc) and Low Myc conditions, respectively 18 . Primary B cells from wild type and homozygous c-myc f/f conditional knockout animals 35 were purified by negative selection with the B Cell Isolation Kit (Miltenyi Biotech). After exposure to a recombinant tat-Cre protein (50 mg ml 21 for 1 h in optimem 1 1% serum) 36 in order to induce deletion of the c-myc f/f allele, splenocytes were stimulated with LPS (50 mg ml
21
; Sigma, L6237) in DMEM and IMDM (ratio 1:1), 10% serum, 1% glutamine, 1% NEAA, 1% penicillin/streptomycin and 25 mM b-mercaptoethanol
37
. Deletion efficiency was checked by qPCR on genomic DNA.
3T9 c-myc f/f and 3T9 MycER fibroblasts were grown in DMEM medium supplemented with 10% serum, penicillin/streptomycin and 2 mM L-Gln. The role of endogenous Myc in 3T9 c-myc f/f cells was studied by deleting the c-myc f/f allele through activation of a conditional CreER chimaera in quiescent cells before serum stimulation, as previously described 8 . Deletion efficiency was checked by qPCR on genomic DNA. To generate the 3T9 MycER line, the 3T9 c-myc f/f cells were infected with a pBabe-Bleo retrovirus 38 encoding the MycER chimaera
39
. Cells were selected with 400 mg ml 21 zeocin (Invitrogen, 46-0509) for one week and kept in zeocin-free medium for subsequent experiments. Single-cell clones were derived and tested for 'leakiness', that is, activation of MycER in the absence of OHT: a non-leaky clone (number 14) was used for all experiments described here. MycER was activated by the addition of 400 nM 4-hydroxytamoxifen (OHT) or ethanol (vehicle control). All cell lines were tested for Mycoplasma in our tissue culture facility before usage. Chromatin immunoprecipitation. Fixation of cultured cells and their processing for chromatin immunoprecipitation (ChIP) were performed as described 40 , except for blocking protein A-Sepharose beads with tRNA (Sigma) instead of salmon sperm DNA and purifying immunoprecipitated DNA through Qiaquick columns (Qiagen) instead of phenol-chloroform extraction. The following adjustments were made for in vivo analysis. MACS-sorted splenic B cells or dissected lymphomas were resuspended in PBS with 0.5% BSA and 2 mM EDTA at room temperature and fixed by addition of 1% formaldehyde for 10 min. Fixation was stopped by addition of 0.125 M glycine. Cells were washed three times in PBS, resuspended in SDS buffer (50 mM Tris at pH 8.1, 0.5% SDS, 100 mM NaCl, 5 mM EDTA and protease inhibitors) and stored at 280 uC before further processing for ChIP 40 . To minimize inter-individual variation we decided to process ChIP samples of control and pre-tumoral mice in pools of at least ten animals, however, due to the clonal nature of lymphomas we kept tumour samples separated. For ChIP-Seq analysis of Myc and RNAPII, lysates from 30 3 10 6 B cells or 50 3 10 6 3T9 fibroblasts were immunoprecipitated with 10 mg of the corresponding antibody (see below). For histone marks, lysates from 5 3 10 6 B cells or 3T9 MycER fibroblasts were immunoprecipitated with 3 to 5 mg of the corresponding antibody pre-bound to G-protein coupled paramagnetic beads (Dynabeads) in PBS, 0.5% BSA. After overnight incubation, beads were washed 6 times in a modified RIPA buffer (50 mM Hepes pH 7.6, 500 mM LiCl, 1 mM EDTA, 1% NP-40, 0.7% Na-deoxycholate) and once in TE containing 50 mM NaCl. DNA was eluted in TE/2% SDS and crosslink reversed by incubation overnight at 65 uC. DNA was then purified by Qiaquick columns (Qiagen) and quantified using PicoGreen (Invitrogen). Then 2-10 ng ChIP DNA was prepared for Solexa Genome Analyzer or HiSeq2000 sequencing with TruSeq ChIP Sample Prep Kit (Illumina) following the manufacturer's instructions, except for the H3K4me3 ChIP-seq in P493-6 cells for which libraries were produced as published 41 . Antibodies. The following antibodies were used for ChIP: H3K4me1 (Abcam, ab8895), H3K27ac (Abcam, ab4729), H3K4me3 (Active Motif, #39159), Myc N262 (Santa Cruz, sc-764) and RNAPII N20 (Santa Cruz, sc-899). Normal rabbit IgG (Santa Cruz, sc-2027) was used as background control. All antibodies were ChIP-grade, as specified by the manufacturer. For western blot: Myc Y69 (Abcam, ab32072), Vinculin (Sigma, V9264). RNA extraction and analysis. Total RNA was purified onto RNeasy columns (Qiagen) and treated on-column with DNase (Qiagen). Complementary DNA (cDNA) was produced using the reverse-transcriptase ImPromII (Promega). A total of 10 ng of cDNA was used for real-time PCR reactions with FAST SYBR Green Master Mix (Applied Biosystems). A total of 100 ng of total RNA were processed for NanoString analysis as described by the manufacturer. For RNAseq, total RNA from 10 7 cells was purified using TRIzol (Invitrogen), treated with Turbo DNase (Ambion) and purified with RNA Clean XP (Agencourt). Then 5 mg of purified RNA was treated with Ribozero rRNA removal kit (Epicentre) and ethanol precipitated. RNA quality and removal of rRNA were checked with the Agilent 2100 Bioanalyser (Agilent Technologies). Libraries for RNA-seq were then prepared with the TruSeq RNA Sample Prep Kits v2 (Illumina) following manufacturer instruction (except for skipping the first step of mRNA purification with poly-T oligo-attached magnetic beads). 4sU labelling. Treatment of 3T9
MycER fibroblasts with 4-thiouridine (4sU, Sigma T4509), isolation and sequencing of 4sU-labelled RNA were performed as previously described 42 with minor modifications. Briefly, cells were labelled with 300 mM 4sU for 10 min. Medium was removed and cells were put on ice, washed 3 times, scraped and pelleted in ice-cold PBS. RNA was extracted with the Qiagen miRNeasy kit according to the manufacturer's instructions including the recommended DNase I digest. 50 mg of total RNA was used for the biotinylation reaction. RNA was diluted in 100 ml of RNase-free water. 100 ml of biotinylation buffer (2.53 stock: 25 mM Tris pH 7.4, 2.5 mM EDTA) and 50 ml of EZ-link biotin-HPDP (1 mg ml 21 in DMF; Pierce/Thermo Scientific 21341) were added and incubated for 2 h at room temperature. RNA was precipitated and unbound biotin-HPDP was removed by a combination of chloroform/isoamylalcohol (24:1) precipitation with purification using MaXtract high density tubes from Qiagen. Biotinylated RNA was purified using Dynabeads MyOne Streptavidin T1 (Invitrogen). Before addition of RNA, 50 ml of beads were washed 2 times in washing buffer A (100 mM NaOH, 50 mM NaCl) and once in washing buffer B (100 mM NaCl). Beads were resuspended in 100 ml of buffer C (2 M NaCl, 10 mM Tris pH 7.5, 1 mM EDTA, 0.1% Tween-20) to a final concentration of 5 mg ml
21
. RNA was added in an equal volume and rotated at room temperature for 15 min. Beads were washed 3 times with washing buffer D (1 M NaCl, 5 mM Tris pH 7.5, 0.5 mM EDTA, 0.05% Tween-20). RNA was eluted from the beads in 100 ml of 10 mM EDTA in 95% formamide (65 uC, 10 min). RNA was extracted with the RNeasy MinElute Spin columns from Qiagen according to the manufacturer and eluted in 14 ml of RNase-free water. RNA quality was assessed using the Agilent 2100 Bioanalyzer (Agilent Technologies). The 4sU-sequencing library was prepared with the TruSeq RNA Sample Prep Kits v2 (Illumina) following the manufacturer's instructions starting from the RNA fragmentation step. DNase I hypersensitivity. Genome-wide sequencing of DNase I hypersensitive sites (DNase I seq) was performed as described 43, 44 . Briefly, 3T9 MycER fibroblasts were treated with OHT for 4 h. Cells were washed with PBS, trypsinized, pelleted (1,300 r.p.m., 5 min, 4 uC) and washed once more with PBS. Pipetting in the following steps was performed with cut tips to avoid DNA breaks due to pipetting force. Cells were resuspended in buffer A (15 mM Tris-HCl pH 8, 15 mM NaCl, 60 mM KCl, 1 mM EDTA pH 8, 0.5 mM EGTA pH 8, freshly supplemented with 0.5 mM spermidine and 0.15 mM spermine). An equal volume of lysis buffer (buffer A with 0.1% NP-40) was added and the cells were incubated on ice for 10 min. Nuclei were pelleted, washed once with buffer A and then resuspended at a concentration of 50 3 10 6 nuclei per ml. Then 10 7 nuclei were diluted with an equal volume of 23 DNase I reaction buffer (Roche). DNase I (Roche, 04716728001) was added at increasing concentrations (0, 100, 200, 300, 400, 500 U ml
) and DNA was digested for 10 min at 37 uC. An equal volume of Stop buffer (50 mM Tris-HCl pH 8, 100 mM NaCl, 0.1% SDS, 100 mM EDTA pH 8, freshly supplemented with 0.5 mM spermidine, 0.15 mM spermine and 10 mg ml 21 of RNase A) was added. Samples were incubated at 55 uC for 30 min (220 r.p.m. agitation). Then 0.2 mg ml 21 of proteinase K was added and samples were incubated at 55 uC overnight (220 r.p.m.). DNA was extracted using a standard phenol-chloroform extraction protocol, dissolved in 100 ml of TE (55 uC, 2 h). Then 300 ng of DNA of each digested sample was checked on an agarose gel for the appearance of a smear of slightly digested DNA. Small molecular weight DNA was purified using AMPure beads (Agencourt AMPure XP Reagent, A63881). The digested DNA samples (100 ml) were supplemented with 50 ml of AMPure beads, 150 ml of 20% PEG buffer (20% PEG8000, 2.5 M NaCl) and incubated for 15 min at room temperature. Beads were separated LETTER RESEARCH on a magnet, washed twice with 80% ethanol and small molecular weight DNA was eluted in 100 ml of 5.5% PEG buffer. The eluted DNA was purified once more (20 ml of beads; 120 ml of 20% PEG buffer) and after washing eluted in 20 ml of H 2 O. DNase I performance was checked by qPCR and samples for sequencing were selected based on the highest signal-to-noise ratio based on selected genomic regions (with 200-300 U ml 21 of DNase I). Chosen samples were size-selected on an agarose gel, small molecular weight DNA (,500 bp) was eluted from the gel with a Qiagen Gel purification kit according to the manufacturer's instructions. Up to 10 ng DNA was prepared for HiSeq2000 sequencing with TruSeq ChIP Sample Prep Kit (Illumina) following the manufacturer's instructions. Primer design and list of primers. Primers for ChIP and mRNA analysis were designed by using computer assisted primer design software (Primer3). The complete list of primers used in this study is shown in Supplementary Table 3 . Immunoblot analysis. 5 3 10 6 to 10 3 10 6 B cells were lysed with RIPA buffer (20 mM HEPES at pH 7.5, 300 mM NaCl, 5 mM EDTA, 10% glycerol, 1% Triton X-100, supplemented with protease inhibitors (Mini, Roche) and phosphatase inhibitors 0.4 mM ortovanadate, 10 mM NaF) and sonicated. Cleared lysates were electrophoresed and immunoblotted with the indicated primary antibodies. Chemiluminescent detection, after incubation of the membranes with appropriate secondary antibodies, was done through a CCD camera using the ChemiDoc System (Bio-Rad). Quantification of protein levels was done using the Image Lab software (Bio-Rad, version 4.0). Proliferation and cell size analysis. To measure cell size, 500,000 live cells were resuspended in 500 ml of PBS and 40,000 total events were collected using a FACSCalibur machine (Becton Dickinson). Propidium iodide (PI) staining solution was added to exclude dead cells from the analysis. Data were then analysed by using FlowJo software (TreeStar) and the mean of PI negative population scored. BrdU incorporation was analysed as described 45 . Cell proliferation was monitored using the CellTiter-Glo Luminescent Cell Viability Assay (Promega). NanoString analysis. For quantitative mRNA measurements on the NanoString platform 46 , we used four nCounter Reporter CodeSets. (1) A custom CodeSet was used for monitoring gene expression in the Em-myc model (Supplementary Table  4 , Fig. 2f ), for which we selected 754 genes (among which 458 were bound at their promoter by Myc in T) covering the whole expression range and regulatory patterns seen by RNA-seq, including 25 genes classified as non-expressed and 5 housekeeping genes (Crocc, Sdha, Tbp, Tubb1 and Tubb4). MycER cells (Fig. 3d) . This CodeSet includes the following 55 genes: Arntl, Ddx58, Olfml2b, Ypel5, Lasp1, Vwa5a, Hsd17b11, Clec2d, Ctso, Prmt2, Myc, Capg, Crocc, Ubb, Dusp6, Rplp0, Car12, Tbp, Mycn, Cdca7l, Hpdl, Ifrd2, Hapln4, Efna3, Polr1b, Slc16a1, Slc19a1, Elovl4, Tfrc, Nnolc1, Wdr73, Zc3h8, Polr3g, Adi1, Fam136a, Bzw2, Wdr55, Taf4b, Mars2, Rrp9, Rragb, Slc25a33, Pdxp, Ica1, Smpdl3b, Dyrk3, Dgat2, GluI, Ifi30, Nr1d1, Reep6, Slc38a3, St6galnac4, Ankrd6 and Smtnl2. Data for these genes are provided in exactly the same order (sorted from left to right) in Fig. 3d. (4) A pre-designed NanoString CodeSet, the Human Cancer Reference Kit (GXA-CR1), was used for the experiments with P493-6 cells (Extended Data Fig. 6c ).
Dedicated nCounter software was used for data analysis, and raw counts were normalized on the geometric mean of the internal positive control probes included in each CodeSet. Data were plotted either without further normalization, or normalized to cell equivalents (based on the total RNA recovered per cell in each single sample). Statistical analysis. All the experiments were performed on biological replicates unless otherwise specified. Sample size was not predetermined and is reported in the respective figure legends. Two-tailed Student's t-test was used to calculate P values; significant values are specified in the figure legends. Computational analysis NGS data filtering and quality assessment. ChIP-seq and RNA-seq NGS reads sequenced with the Illumina HiSeq2000 were filtered using the fastq_quality_ trimmer (setting the options to 2Q33 2t 20 2l 10) and fastq_masker (setting the options to 2q 20 2r N) tools of the FASTX-Toolkit suite (http://hannonlab. cshl.edu/fastx_toolkit/). Their quality was evaluated and confirmed using the FastQC application (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Analysis of ChIP-seq data. ChIP-seq NGS reads were aligned to the mm9 (Em-myc and 3T9 fibroblasts data) and hg19 (P493-6) genomes through the BWA aligner using default settings 47 . Peaks were called using the widely used MACS software (v1.4) 48 . Only peaks with P values , 1 3 10 28 were retained (positive peaks). MACS was also used to perform saturation analysis (as a control of false negatives) and to determine an estimated false discovery rate (as a control of false positives) for each experiment. In the saturation analysis, the fraction of peaks confirmed with 80% of the reads was determined. For most of the samples this fraction was higher than 60%. False discovery rate was determined as the proportion of negative vs. positive peaks. Negative peaks were identified by calling MACS on the input samples, using the ChIP as reference. False discovery rates were typically lower than 5-10%.
Normalized reads count within a genomic region was determined as the number of reads per million of library reads (total number of aligned reads in the sequencing library). Peak enrichment was determined as log 2 (ChIP w 2 input w ), in which ChIP w and input w is the normalized count of reads in the peak region in the ChIP and in the corresponding input sample. Myc P binding sites are defined as the union of peaks over 3 ChIP-seq experiments on independent P samples. Enhancers are defined as distal H3K4me1 peaks, that is, peaks not overlapping with promoters (22 kb to 11 kb from TSS) and not associated with CpG islands (CGIs).
The RNA polymerase II stalling index (SI, also called elongation rate) 30,49 was calculated as SI 5 Prom/GB; prom refers to the read counts on the promoter (TSS 6 300 bp interval) and GB to the read counts in the gene body (the interval between TSS 1301 and 3,000 bp after the TSS). These values were normalized both to library size (total number of reads) and to the length of the interval, and only genes with GB . 600 and with a RNAPII ChIP-seq peak in the region [TSS 22,000; TSS 1 1,000 bp] were considered. RNA-seq data analysis. RNA-seq NGS reads were aligned to the mm9 mouse reference genome using the TopHat aligner (version 2.0.6) with default parameters 50 . For Em-myc data read counts were associated to each gene (based on UCSC derived mm9 GTF gene annotations) using the HTSeq software (http://wwwhuber.embl.de/users/anders/HTSeq/doc/overview.html) setting the options -q --mode5intersection-nonempty --stranded5no. Absolute gene expression was defined determining RPKM as previously described 51 . Differentially expressed genes (DEGs) were identified using the Bioconductor 52 package DESeq 53 based on read counts, considering genes whose q value relative to the control is lower than 0.05 and whose maximum expression is higher than RPKM of 3.
For 3T9 MycER data, read counts were defined for each gene isoform as the sum of the read counts over all exons. Exon read counts were determined based on the TxDb.Mmusculus.UCSC.mm9.knownGene Bioconductor 52 annotation library using the countOverlaps Bioconductor 52 method. We calculated the read counts of a gene with more than one isoform as the rounded mean of the counts of its isoforms. The absolute expression of a gene in both RNA-seq and 4sU-seq was estimated through RPKM as previously described 51 , defining total library size as the number of reads mapping to exons only. This is due to the fact that 4sU-seq library shows a marked enrichment in the reads mapping over intronic features compared to the RNA-seq library 42 . Therefore, in order to compare the expression of genes in both types of libraries, we measured library sizes using the reads mapping over exonic features only. DEGs were identified using the Bioconductor 52 package DESeq2, considering genes whose q value relative to the control is lower than 0.01 and whose minimum expression in all samples is higher than RPKM of 1.
For both Em-myc and 3T9 MycER RNA-seq data, samples were normalized using DESeq and DESeq2 based on scaling factors, assuming that most genes are not differentially expressed. For each gene the scaling factor is computed as the median of the ratio of its read counts over its geometric mean across all samples. Other bioinformatic analysis. Bioinformatics and statistical analysis, including heatmaps of ChIP-seq data, GeneOntology enrichment, and hierarchical clustering of RNA-seq data were performed using R and Bioconductor packages. R scripts, data, and the R code used to reproduce bioinformatics and statistical analyses are available at (http://genomics.iit.it/supplementalData/SaboNature2014). . d, ChIP-seq tracks at the same target genes. The maxima of the tracks are 100 for Ncl, 50 for Ubfd1 and 30 for Dusp6. e-g, ChIP-seq quality controls in the Em-myc data set. e, ChIP-seq saturation analysis for Myc peaks of different enrichment levels for a representative tumour (T1). In this analysis a random subset of the reads is removed (down-sampling) and the number of identified peaks in the down-sampled data set is compared to the full data set. If most of the peaks are confirmed upon down-sampling, the ChIP-seq is considered to be well saturated. f, Distribution of reads density (library size normalized) for Myc-bound or unbound promoters, as indicated (Myc1, Myc2). 20,000 random 3 kb regions not overlapping with promoters were used to assess background. The Myc signal in unbound promoters (red) is close to the background (grey). g, Validation of ChIP-seq peaks by qPCR. We designed PCR amplicons at 42 sites that correspond to the following categories in Emmyc: (1) genes that are either not or barely expressed (RPKM , 4) and show no Myc binding in their promoter according to our ChIP-seq analysis (cyan), (2) genes that are expressed (RPKM . 4) but not bound by Myc (red), (3) genes that are both expressed and bound (black). An IgG antibody was used as negative control: the grey dotted lines indicate the 20th and 80th percentiles of the IgG signal. The left panel shows enrichment determined by ChIP-qPCR relative to that in ChIP-seq. ChIP DNA from C, P and T samples was used to amplify each test site. The right panel shows the distribution of signals obtained in ChIP-qPCR for the different categories of genes along with the signal obtained for all amplicons with the IgG antibody (grey). h, Pie charts showing the number and percentage of promoter, intergenic and intragenic Myc peaks in C, P and T samples (T1, T2, T3), based on the genomic position of each peak's midpoint. The number above each chart gives the total amount of peaks. i, Overlap between Myc ChIP-seq peaks. For each column the percentage of peaks overlapping (at least 1 bp) with the reference samples is reported. j, Box plot showing the net distance of Myc from the nearest TSS (upstream and downstream sites together). *P , 0.05, **P , 0.001. RESEARCH LETTER
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